CDKN2A and ovarian carcinoma: Among these five lncRNAs for signature construction, CDKN2A-DT (CDKN2A-AS1) has been demonstrated to promote epithelial ovarian cancer growth and progression through activating the BMP-SMAD pathway (Zhao et al., 2021).